Eleonora Ioannidi

Eleonora Ioannidi

Auto-generated profile, based on publicly available information

Eleonora Ioannidi

Institute of Pharmacology and Toxicology, University of Zurich

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
DBDesirée Böck
Desirée Böck
LTLisa Tidecks
Lisa Tidecks
MWMaria Wilhelm
Maria Wilhelm
YWYanik Weber
Yanik Weber
EIEleonora Ioannidi
Eleonora Ioannidi
GSGerald Schwank
Gerald Schwank
Summary: Prime editing is a highly versatile genome editing technology that holds great potential for treating genetic diseases 1, 2 . While in vivo prime editing has recently been conducted in the brain, liver, heart, and retina 3–6 , application of this technology to modulate neural circuits in the brain has not been reported yet. Here, we employ adeno-associated viral vectors to deliver optimized intein-split prime editors into the brain of mice. Delivery into newborn pups via intracerebroventricular injection resulted in up to 44.0% editing at the Dnmt1 locus in the cortex (on average 34.8±9.8% after 6 months). In addition, we obtained up to 28.1% editing at the Adrb1 locus in the cortex (on average 14.7±11.6% after 6 months). The introduced Adrb1 A187V mutation is a naturally occurring variant of the β1-adrenergic receptor, which has previously been linked to increased activity and natural short sleep 7 . Similarly, we observed an increase in the activity and exploratory behavior of treated animals. This study demonstrates the potential of prime editing for treating genetic diseases in the central nervous system and for reprogramming molecular pathways that modulate animal behavior.